News Summary
Kindeva Drug Delivery celebrated the opening of its expanded facility in Lexington, enhancing production of nasal sprays. The over 70,000-square-foot site aims to meet increasing demand for essential nasal medications, create job opportunities, and support local educational partnerships. Kindeva plans to transition to a seven-day production schedule, indicating its commitment to addressing the rising market needs.
Lexington – Kindeva Drug Delivery officially celebrated the opening of its expanded location in Lexington on Thursday, marking a significant ramp-up in the production of its nasal sprays. This expansion is expected to enhance the company’s ability to meet rising demand for these vital medications.
The newly opened facility is situated at the UK Coldstream Research Park and spans over 70,000 square feet. This larger space enables Kindeva to not only increase production capabilities but also adapt to the growing market needs for nasal-based medications.
Kindeva’s product line primarily includes nasal sprays used for various health applications, such as reversing opioid overdoses, treating migraines, and alleviating symptoms of post-traumatic stress disorder. The evolution of Kindeva can be traced back to its inception as Summit Biosciences in 2009, driven by university research conducted at the University of Kentucky. In 2024, Kindeva acquired Summit Biosciences, paving the way for this recent expansion.
As the demand for nasal delivery systems increases, Kindeva is responding by adding a third shift to its manufacturing schedule. The Vice President indicated that the company has experienced consistent year-over-year sales growth in nasal-based medicines, which are vital not only in the U.S. but also in international markets like Australia and Europe. Kindeva plans to transition from a five-day to a seven-day production schedule within the next 18 to 24 months, further reflecting its commitment to meeting demand.
The expansion is also expected to create numerous job opportunities in the region. Currently, Kindeva employs over 150 individuals and is looking to hire for various roles ranging from entry-level manufacturing to engineering positions. The company collaborates with local organizations such as Commerce Lexington and educational institutions, including the University of Kentucky and Bluegrass Community and Technical College, to help recruit talent and provide opportunities for young individuals interested in entering the pharmaceutical manufacturing field.
At a ceremony celebrating the expansion, the President of the University of Kentucky, Eli Capilouto, acknowledged Kindeva’s growth and its ties to the local culture. He emphasized how the expansion serves as a significant milestone for the company and the surrounding community, particularly in providing educational and employment pathways.
The establishment of the new facility not only reflects Kindeva’s growth but also the increasing relevance of nasal delivery systems in modern medicine. By enhancing production capabilities, Kindeva aims to ensure that they can continue to deliver critical medications effectively while supporting local economic growth through job creation.
In summary, Kindeva Drug Delivery’s expanded operations in Lexington signify an essential step forward for the company, poised to meet the escalating demand for nasal spray medications while fostering local employment and collaborating closely with educational institutions.
Deeper Dive: News & Info About This Topic
HERE Resources
Additional Resources
- Kentucky News
- Wikipedia: Nasal Spray
- Business Wire
- Google Search: Nasal Drug Delivery Systems
- Drug Delivery Business
- Encyclopedia Britannica: Pharmaceutical Drug
